 |
인쇄하기
취소
|
Bukwang's clevudine to grab bigger market share
Bukwang Pharm is expected to expand its market share of the domestic anti-hepatitis B drug market dominated by GlaxoSmithKline (GSK), analysts said.
Clevudine, the first-domestically-made medication for hepatitis B and licensing-in entity, is challenging Zeffix and Hepsera of GSK.
It received approval from the nation's food and drug authorities on Jul6 28.
Analysts forecast clevudine ...
Clevudine, the first-domestically-made medication for hepatitis B and licensing-in entity, is challenging Zeffix and Hepsera of GSK.
It received approval from the nation's food and drug authorities on Jul6 28.
Analysts forecast clevudine ...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.